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Introduction: This phase III study compared efficacy and safety 
of topotecan-cisplatin (TP) versus topotecan-etoposide (TE) versus 
cisplatin-etoposide (PE) in chemo-naïve extensive disease small-cell 
lung cancer patients.
Methods: Seven hundred and ninety-five previously untreated 
patients were randomly assigned to TP (topotecan 1mg/m2 IV, d1–5; 
cisplatin 75mg/m2 IV, d5; n = 358), PE (cisplatin 75 mg/m2 IV, d1; 
etoposide 100 mg/m2 IV, d1–3; n = 345) or TE (topotecan 1mg/m2 IV, 
d1–5; etoposide 80 mg/m2 IV, d3–5; n = 92). Primary endpoint was 
superiority of TP compared with PE, with the possibility to switch to 
a noninferiority test.
Results: The TE arm was closed after recommendations by the 
Independent Data Safety Monitoring Board. Median survival was 
similar and met the predefined endpoint of noninferiority of TP to PE 
(44.9 versus 40.9 weeks; p = 0.40). One-year survival rate showed 
39.7% for TP versus 36.1% for PE (p = 0.29). Median time to pro-
gression was significantly longer with TP (27.4 versus 24.3 weeks, 
p = 0.01). Overall response rates were significantly higher for TP 
(55.5% versus 45.5%, p = 0.01).
Hematologic toxicity was slightly higher for TP regarding G 3/4 
neutropenia (35.7/35.8%), G 3/4 thrombocytopenia (18.7/4.8%), 
G 3/4 anemia (11.6/6.7%), febrile neutropenia (2.0/2.7%), sepsis 
(1.7/1.2%), and toxicity-related deaths (5.2/2.7%).
Conclusion: TP is noninferior to PE in overall survival and superior 
in time to progression and overall response rates. Because of slightly 
worse toxicity profile TP is not a first-line standard treatment for 
patients with extensive disease small-cell lung cancer.
Key Words: Small-cell lung cancer, First-line chemotherapy, 
Topotecan.
(J Thorac Oncol. 2012;7: 1432–1439)
For almost 30 years, the cisplatin and etoposide combina-tion has represented the current standard first-line regi-
men worldwide in extensive disease small-cell lung cancer 
(ED-SCLC). This regimen leads to a median overall survival 
of 8.4 to 10.2 months and a 2-year survival rate of approxi-
mately 5% because the vast majority of patients experience 
relapse after 6 to 8 months.1,2 This short overall survival time 
calls for more active treatments.
Topotecan (Hycamtin; GlaxoSmithKline, Middlesex, 
United Kingdom), a camptothecin derivative, specifically 
inhibiting topoisomerase I, has shown promising results in 
relapsed sensitive SCLC.3 Topotecan is approved for the sec-
ond-line treatment of SCLC at a dosage of 1.5 mg/m² once 
daily on 5 consecutive days every 3 weeks. Comparison of 
single-agent topotecan to the triple-agent therapy cyclophos-
phamide, doxorubicin, vincristine (CAV) resulted in similar 
response rates, median time to progression (TTP), and median 
survival in second-line treatment in 211 patients with ED 
SCLC.4 In first-line treatment 19 of 48 patients (39%) achieved 
a partial remission, with a median survival of 10 months and 
a 1-year survival rate of 39% in a phase II study.5 In addition, 
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a large randomized Eastern Cooperative Oncology Group 
(ECOG) study conducted by Schiller et al.6 showed that topo-
tecan maintenance therapy after cisplatin/etoposide caused an 
increase in progression free survival (PFS) time, but did not 
improve the overall prognosis of the patients.
Experience with topotecan combination therapy in first-
line treatment was very limited at the time of the study initia-
tion. Sorensen et al.7 combined topotecan at a dosage of 1.5 mg/
m²/d, days 1 to 5, with cisplatin 50 mg/m² on day 5. A total of 
21 patients were treated. The dosage used was well tolerated 
without any major toxicities. In a phase II study conducted 
by Seifart et al.8 compared the administration of topotecan/
cisplatin for 5 days versus 3 days in the treatment of extensive 
stage small-cell lung cancer. It could be demonstrated that the 
doses used for the present phase III trial were safe and that 
the activity of the treatment regimen was at least within the 
range of established regimens. The results showed an encour-
aging overall response rate of 62% for the 5-day regimen ver-
sus a 60% overall response rate for the 3-day regimen with 
mild toxicity in general. The present open-label, multicenter, 
randomized phase III study was undertaken to compare the 
safety and feasibility of an experimental arm topotecan-cispl-
atin (TP) with the standard arm physical examination (PE) in 
patients with ED-SCLC.
PATIENTS AND METHODS
Patient Selection
Patients with ED-SCLC were randomized 1:1 from 84 
centers in Germany and Austria. A third treatment arm using 
topotecan plus etoposide (TE) was prematurely discontinued 
after the treatment of 92 patients because of unacceptable tox-
icities as judged by an Independent Data Safety Monitoring 
Board. The data reported summarize the comparison of TP 
versus PE only.
Eligible patients had histologically or cytologically con-
firmed ED-SCLC and had to fulfill the following main inclu-
sion criteria: presence of either measurable or nonmeasurable 
disease by radiological imaging or PE; age 18 to 75 years; 
recovery of patients from any reversible toxic effects after pal-
liative radiotherapy; adequate bone marrow, adequate hepatic 
and renal function; and an ECOG performance status less than 2. 
All patients provided written informed consent. Patients were 
excluded for symptomatic brain metastases, concomitant or 
previous malignancies, active infection, severe comorbidities, 
pregnancy or lactation, hypersensitivity or other contraindi-
cation to the study drugs, preexisting hearing impairment or 
neurotoxicity of such a degree to preclude the use of cisplatin. 
The study was conducted in accordance with the Declaration 
of Helsinki (version 1996) and the applicable International 
Conference on Harmonisation - Good Clinical Practice guide-
lines. The protocol was approved by each of the investigational 
sites ethics committee. Unstratified randomization was per-
formed centrally, in a 1:1 ratio to one of the two treatment arms.
Chemotherapy Regimens
Treatment regimens consisted of the intravenous 
administration of: topotecan 1 mg/m2 from days 1 through 5, 
cisplatin 75 mg/m2 on day 5 in the experimental study arm TP, 
and etoposide 100 mg/m2 from days 1 through 3 and cisplatin 
75 mg/m2 on day 1 in the standard arm PE, every 3 weeks. 
Patients without progressive disease (PD) were to receive all 
six planned courses. Patients with PD were to be withdrawn 
from study treatment and CAV could be given as a second-line 
therapy, if indicated. Patients in the TE group received intrave-
nous topotecan 1 mg/m2 on days 1 through 5 with intravenous 
etoposide 80 to 100 mg/m2 on days 3 through 5, every three 
weeks. Patients were considered to have completed the study 
as planned if they received at least one full course of study 
medication.
Dose Delays and Modifications
Dose adjustments were performed according to toler-
ability. Hematological and non-hematological toxicity was 
assessed according to National Cancer Institute common tox-
icity criteria, version 2.0. The following levels were used for 
dose modification of topotecan: if the leukocyte nadir was less 
than 1 × 109 per liter and/or the thrombocyte nadir less than 
30 × 109 per liter, the dose was reduced by 0.25 mg/m2/d. If 
the leukocyte nadir was more than 3 × 109 per liter and the 
thrombocyte nadir more than 100 × 109 per liter, a single dose 
escalation of topotecan by 0.25 mg/m2/d was allowed (single 
dose ≤ 1.25 mg/m2/d). The minimum dose of topotecan was 
0.5 mg/m2/d. If, at the minimal dose, the treatment course was 
delayed for more than 2 weeks, the patient was withdrawn 
from the study. In case of nephrotoxicity (creatinine clearance 
40–60 ml/min), the cisplatin dose was reduced. Re-escalation 
was not permitted. In case of severe nephrotoxicity (creatinine 
clearance < 40 ml/min), cisplatin was allowed to be replaced 
by carboplatin (dose estimation according to the formula pro-
vided by Calvert et al.).9 No reswitch was permitted.
Statistical Methods
The primary objective was to assess whether TP would 
lead to a superior or at least noninferior overall survival (OS) 
compared with PE in chemo-naive patients with ED-SCLC. 
OS was defined as all-cause mortality and calculated from 
the date of randomization to the date of death or date of last 
follow-up, if the patient was censored.
The chosen group-sequential test for the primary effi-
cacy endpoint scheduled two interim and one final analysis for 
efficacy. The sample size of 350 patients per arm was calcu-
lated based on an assumed median survival time of 8.5 months 
in the PE versus 11.2 months in the TP arm. This sample size 
provides a power of 80% for a two-sided unstratified sequen-
tial log-rank test on a global level of 0.05, based on 29 months’ 
accrual time and 12 months’ follow-up time. Alpha-spending 
for rejection of the null hypothesis was chosen according 
to the O’Brien-Fleming characteristics, whereas stopping 
boundaries for futility were defined according to Pocock.
As this test strategy failed to prove superiority, a noninfe-
riority test was performed subsequently (CPMP/EWP/482/99, 
cf. www.emea.europa.eu/pdfs/human/ewp/048299en.pdf). 
This noninferiority analysis was part of the original study 
design. The margin of noninferiority of TP was defined as a 
10% reduction of the observed median survival time in the PE 
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group. For the noninferiority decision, a two-sided 99% con-
fidence interval (CI) was used instead of the usual one-sided 
97.5% CI with the intention of being sufficiently conservative 
within this sequential design. This approach became necessary 
as the criterion to stop for futility was met at the second interim 
analysis for efficacy. All patients had been in their follow-up 
phase or even off study at that time. Early stopping of the study 
was not feasible anymore and, in consequence, no statistical 
estimator adjusting for the sequential nature of the study could 
be calculated anymore at the very end of the study. The chosen 
approach (two-sided 99% CI) is, however, even more conser-
vative than the planned approach and is thus a fair representa-
tion of the study outcome.
The secondary efficacy variables were exploratory 
tested using the log-rank test, logistic regression model, Cox’s 
proportional hazard ratio model, Cochran Mantel Haenszel χ2 
test, Fisher’s exact test, or Wilcoxon test, as applicable. The 
median time to PD was calculated from the time of initial 
administration of the first dose of chemotherapy until first 
documented evidence of progression or death. For evaluation 
of response patients with measurable disease were assessed 
using the standard World Health Organisation (WHO) criteria 
for complete and partial response and for stable and progres-
sive disease. Two prespecified stratification factors comprised 
performance status at baseline (ECOG 0–1 versus 2) and lac-
tate dehydrogenase level (normal or elevated). They have been 
applied as covariates in the analyses of efficacy, as stated.
Safety data were descriptively analyzed by providing 
absolute and relative frequencies in summary tables based on 
the number of patients or the total number of cycles admin-
istered. Adverse events were coded according to the Medical 
Dictionary for Regulatory Activities (MedDRA) and graded 
according to National Cancer Institute common toxicity criteria.
RESULTS
The results of the study were presented in part at the 
2008 ASCO Annual Meeting by D. F. Heigener, Germany 
(J Clin Oncol 26: 2008 May 20 suppl; abstr 7513).
Patients
From August 2002 to February 2006, a total of 795 patients 
were randomized to treatment (345 in the PE group, 358 in the 
TP group, and 92 in the TE group) with a total of 769 patients 
receiving study medication and being included in the intention-
to-treat (ITT) analysis. Of the 795 patients, 71.1% completed 
the study and 28.9% prematurely dropped out (mostly because 
of severe adverse events in any treatment group). A total of 680 
patients were analyzed together for TP and PE treatment; the 
data of the TE group were not included in this analysis and will 
be reported separately. Demographic and baseline characteris-
tics were balanced between study arms (Table 1).
Delivered Chemotherapy
In the PE arm, 9.3% of the patients, and in the TP 
arm, 10.4% received one cycle of their respective regimen. 
In the PE arm, a median dose of 75 mg/m2 cisplatin and 
100 mg/m2 etoposide was administered in cycles 1 through 
6. In the TP arm a median dose of 1.0 mg/m2 topotecan and 
75 mg/m2 cisplatin was administered in cycles 1 through 6. 
The proportions of patients receiving six cycles were similar 
in each treatment group (PE, 55.7%; TP, 55.2%). The dose 
intensity decreased from cycle 1 to cycle 6 in both treatment 
groups, especially for cisplatin. In both treatment arms, 99.1% 
of the patients received 80% to 120% of the planned dose of 
etoposide or topotecan and cisplatin in cycle 1, whereas in 
cycle 6 the proportion was 98.9% for etoposide and 85% for 
cisplatin in the PE arm, and 97.9% for topotecan and 90.8% 
for cisplatin in the TP arm.
Dose reductions were necessary in 17.6% of patients 
with TP and 14.1% of patients with PE treatment. Course 
delays occurred in 2.7% of patients with PE and 8.4% of 
patients with TP treatment. Cisplatin was more often replaced 
by carboplatin in the PE group than in the TP group (6.0% 
versus 2.9%).
According to the protocol, second-line treatment with 
CAV was recommended. Poststudy treatment was comparable 
in both arms. Chemotherapy was given to 48% in the TP arm 
and 55.4 % in the PE arm. In the TP arm 45.1% and in the PE 
arm 41.6% received radiotherapy. Surgery was accomplished 
in 0.9% (TP) and 1.2% (PE).
Efficacy of Treatment
The median OS (ITT-population) was 44.9 weeks in the 
TP (95% CI, 41.4–48.1 week) and 40.9 weeks in the PE group 
TABLE 1.  Demographic and Baseline Characteristics of 
Patients (Safety/ITT Population)
PE Group  
(n = 334)
TP Group  
(n = 346)
Sex
 Male, n (%) 228 (68.3) 237 (68.5)
 female, n (%) 106 (31.7) 109 (31.5)
Race
 White, n (%) 333 (99.7) 345 (99.7)
 Oriental, n (%) 1 (0.3) 1 (0.3)
Age (yrs)
 Mean ± Std 60.8 ± 8.3 61.3 ± 7.8
 range 38–75 39–75
ECOG
 Grade 0 65 (19.5) 62 (17.9)
 Grade 1 217 (65.0) 225 (65.0)
 Grade 2 51 (15.3) 58 (16.8)
 Grade 3 1 (0.3) 0
LDH
 <1.5 × ULN 199 (59.6) 227 (65.6)
 ≥1.5 × ULN 135 (40.4) 119 (34.4)
Histological type
 Oat cell carcinoma 47 (14.1) 49 (14.2)
 Intermediate cell type 19 (5.7) 22 (6.4)
 Mixed small and large cell type 4 (1.2) 1 (0.3)
 Small cell without specification 264 (79.0) 274 (79.2)
IIT, intention-to-treat; PE, cisplatin-etoposide; TP, topotecan-cisplatin; ECOG, 
Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.
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(95% CI, 36.7–46.1 week). The test for superiority could not 
establish statistical significance as the two-sided log-rank test 
resulted in p = 0.29 (ITT population). To test noninferior-
ity, the lower bound of the calculated CI for the OS in the TP 
group had to be greater than the median OS in the PE group 
minus a delta of 10% in the per-protocol population. Thus, 
the decision threshold was 36.9 weeks (41.0−4.1 week). The 
lower bound of the 99% CI in the TP group for the median OS 
of 44.9 weeks was 40.6 weeks, and hence clearly higher than 
the decision threshold of 36.9 weeks. Therefore, noninferior-
ity in terms of overall survival could be proven in a confir-
matory manner with this study. Primary efficacy analysis is 
provided in Table 2.
Secondary efficacy analyses resulted in statistically 
significant differences for TTP, time to event (progressive 
disease or death) and objective response rate favoring TP. 
Results of the secondary efficacy analyses are summarized 
in Table 3.
Toxicity
The incidence of grade 3/4 hematologic toxicities was 
comparable in the PE and TP arms for neutropenia, febrile 
neutropenia, and sepsis. With regard to grade 3/4 thrombocy-
topenia and grade 3/4 anemia, higher incidences in the TP arm 
were seen (Table 4).
In the TP group, a substantially higher number of trans-
fusions and growth factors were required compared with PE. 
Especially, the number of red blood cell transfusions showed 
a statistically significant twofold higher use for TP (58% TP 
versus 26% PE) (Table 5).
There was a distinct difference in the total number of 
deaths related to study medication (as reported on the SAE 
form), with 5.2% and 2.7% of patients in the TP and the PE 
group, respectively. The total number of deaths during the 
study period was 282 (84.4%) in the PE arm compared with 
283 (81.8%) in the TP arm.
DISCUSSION
The present phase III study was conducted to assess 
the tolerability and activity of TP and PE in patients with 
ED-SCLC. A statistically significant superiority in overall 
survival for TP versus PE (p = 0.40) could not be estab-
lished, but the predefined criteria to show noninferiority for 
TP were successfully met. There was a trend in the 1-year 
survival rate favoring TP and a statistically significant pro-
longation of TTP (p = 0.004). Interestingly, better TTP did 
TABLE 2. Primary Efficacy Analysis
Primary Efficacy Analysis
PE Group (n = 334) TP Group (n = 346)
Overall survival (weeks)
Step 1: Superiority
 N (ITT) 334 346
 Median (95% CI) 40.9 (36.7; 46.1) 44.9 (41.4; 48.1)
 HR (95% CI) 0.92 (0.78; 1.08) p = 0.30 (TP vs. PE)
 Two-sided log-rank test
Step 2: Noninferiority
 N (PP) 329 345
 Median (99% CI) 41.0 (35.7; 47.3) 44.9 (40.6; 49.3)
 HR (95% CI) 0.93 (0.79; 1.10) p < 0.005
 (TP versus PE)
 Noninferiority decision 41 weeks minus Δ = 10%
=> Noninferiority threshold: 36.9 weeks
This noninferiority threshold is thus smaller than 
the lower 99% CI in TP arm: 40.6 weeks)
=> Noninferiority proven
PP, per protocol; TP, topotecan-cisplatin; PE, cisplatin-etoposide.
TABLE 3. Secondary Efficacy Results
Secondary Efficacy Results
PE Group  
(n = 334)
TP Group  
(n = 346)
1-year survival rate (%)
N 109 127
Estimated ratea (95% CI) 36.1 (30.9; 41.4) 39.7 (34.5; 44.9)
Observed rate (95% CI) 32.6 (27.6; 37.7) 36.7 (31.6; 41.8)
Fisher’s exact test p = 0.30
1.20 (0.873; 1.644)/p = 0.23OR (95% CI)/p 
TTPb(weeks)
N 334 346
Median [95% CI] 24.3 (23; 26.1) 27.4 (25.4; 29.6)
Log-rank test (TP vs. PE) p = 0.01
0.81 (0.688; 0.952)/p = 0.01Hazard ratio [95% CI]/pa
Time to response (weeks)
N 334 346
Median (95% CI) 49.0 (46.0; 51.0)
7.0 (6.6; 7.3)
50.0 (48.0; 51.0)
7.1 (6.9; 7.3)
Log-rank test (TP vs. PE) p = 0.24
1.10 (0.927; 1.330)/p = 0.23Hazard ratio (95% CI)/pa
Response duration (weeks)
N 221 255
Median (95% CI) 22.1 (19.7; 24.9) 25.1 (23.0; 28.3)
Log-rank test (TP vs. PE) p = 0.05
0.82 (0.672; 1.001)/p = 0.05Hazard ratio (95% CI)/pa
ORR(%)
N 152 192
ORR (95% CI) 45.5 (40.2; 50.8) 55.5 (50.3; 60.7)
Fisher’s exact test p = 0.01
1.493 (1.104; 2.021)/p = 0.01OR (95% CI)/p
LCSS (AUC by timec)
Mean AUC (95% CI) 51.9 ± 17.2 (50.0; 53.8) 54.3 ± 17.7  
(52.4; 56.3)
Wilcoxon rank sum test p = 0.19
aCox proportional hazard ratio model with center, baseline Eastern Cooperative 
Oncology Group and baseline lactate dehydrogenase as covariates.
bProgressive disease or death.
cAUC of LCSS over the course of treatment divided by time in study.
TP, topotecan-cisplatin; PE, cisplatin-etoposide; CI, confidence interval; ORR, 
overall response rate; OR, observed rate; TTP, time to progression; LCSS, Lung Cancer 
Symptom scale; AUC, area under curve.
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not translate into better OS, although poststudy treatment 
was not different in both arms. Moreover, a statistically 
significant higher response rate was observed for TP com-
pared with PE (p = 0.01). Although both schedules were 
well tolerated, the efficacy data are compromised by a higher 
degree of toxicity in the TP arm, especially hematological 
toxicity. This disadvantage is documented by a higher inci-
dence of grade 3/4 thrombocytopenia, grade 3/4 anemia, 
and toxicity-related deaths. Furthermore, the transfusion of 
red blood cell units and platelets were more than twofold 
higher for TP. Because of its toxicity profile, the TP regimen 
is unlikely to replace PE as the standard first-line treatment 
in SCLC but still plays an important role in the relapsed 
situation. In the past decade, several new drugs have been 
tested in ED-SCLC to improve overall outcome. The addi-
tion of paclitaxel10 or gemcitabine11 to carboplatin showed 
similar activity in comparison to PE, whereas pemetrexed 
was clearly inferior to PE.12 Topoisomerase I inhibitors rep-
resent promising agents in the treatment of ED-SCLC, based 
on their well-established activity in second line. Eckardt et 
al.2 conducted a study comparing oral topotecan-cisplatin TP 
with PE in first-line treatment of ED-SCLC. Patients were 
randomly assigned to receive oral topotecan 1.7 mg/m2, days 
1 to 5 with intravenous (IV) cisplatin 60 mg/m2 on d5 or IV 
etoposide 100 mg/m2, days 1 to 3 with IV cisplatin 80 mg/
m2 on d1, every 3 weeks. Similar efficacy regarding overall 
survival could be observed for both treatment regimens (TP 
39.3 weeks versus PE 40.3 weeks, p = 0.48) with PE achiev-
ing statistically significant longer TTP (p = 0.02; median: 
TP 24.1 weeks versus PE 25.1 weeks). Regarding OS, these 
results are in accordance with the findings of our study and 
underline the activity of oral as well as IV TP. However, the 
efficacy data seem to favor the IV application, whereas tox-
icity was worse with oral topotecan.
The topoisomerase I inhibitor irinotecan has also 
been tested in several trials in recent years. In 2002, Noda 
et al.13 presented data comparing irinotecan/cisplatin (IP) 
versus cisplatin/etoposide (PE) in Japanese patients with 
untreated first-line ED-SCLC. The patients were randomly 
assigned to receive IP (irinotecan 60 mg/m2, days 1, 8, 
and 15, and cisplatin 60 mg/m2, day 1, every 4 weeks) or 
PE (cisplatin 80 mg/ m2, day 1 and etoposide 100 mg/m2, 
days 1–3, every 3 weeks). Statistically significant superior 
survival for the patients treated in the experimental study 
arm (IP: 12.8 months versus PE: 9.4 months, p = 0.002) 
was observed. A confirmatory study conducted in 2005 by 
Hanna et al.14 in a North American patient population could 
not confirm the increased survival noted in the Noda trial. 
Patients in this trial were randomly assigned 2:1 to receive 
cisplatin 30 mg/m2 plus irinotecan 65 mg/m2, days 1 and 
8 every 3 weeks, or cisplatin 60 mg/m2, day 1 and etopo-
side 120 mg/m2, days 1 to 3, every 3 weeks. Natale et al.15 
recently presented data from a North American patient 
population with a treatment schedule that was exactly the 
same as in the Noda trial. In more than 600 patients, no dif-
ferences were noted in response, PFS, and overall survival. 
The observed divergence in the results of the Noda trial and 
that of the North American study is not fully explainable. 
It is conceivable that pharmacogenomic differences in drug 
metabolism have contributed to a higher efficacy of irino-
tecan in Asian patient populations compared with efficacy 
in American or European cohorts.
In conclusion, the results of the present study show 
that the combination of IV topotecan/cisplatin is an active 
regimen in ED-SCLC and is noninferior to the standard PE. 
TP is associated with a higher percentage of hematologi-
cal toxicities resulting in higher transfusion rates especially 
for red blood cells. Also a higher rate of treatment-related 
deaths was observed but did not show statistical signifi-
cance. Despite higher response rates and longer PFS, TP 
will not replace standard PE in the first-line management 
of ED-SCLC because of the higher degree of toxicity. 
TABLE 4.  Grade 3/4 Toxicities
Patients with
Eto + Cis (PE) 
(n = 334) n (%)
Topo + Cis (TP) 
(n = 346) n (%) pa
Neutropenia
 Grade 3 77 (23.1) 118 (34.1) 0.002
 Grade 4 126 (37.7) 94 (27.2) 0,004
Febrile neutropeniab 9 (2.7) 7 (2.0) n.s.
Sepsis 4 (1.2) 6 (1.7) n.s.
Thrombocytopenia
 Grade 3 39 (11.7) 127 (36.7) <0.0001
 Grade 4 8 (2.4) 24 (6.9) 0.006
Anemia
 Grade 3 47 (14.1) 95 (27.5) <0.0001
 Grade 4 3 (0.9) 12 (3.5) 0.034
Nausea 15 (4.5%) 20 (5.8%) n.s.
Vomiting 15 (5.1%) 16 (4.6%) n.s.
Alopecia 15 (4.5%) 9 (2.6%) n.s.
Fatigue 8 (2.4%) 11 (3.2%) n.s.
Diarrhea 5 (1.5%) 10 (2.9%) n.s.
Dyspnea 13 (3.9%) 12 (3.6%) n.s.
Renal failure 5 (1.5%) 1 (0.3%) n.s.
aMultiple comparisons, unadjusted p values.
bFever > 38°C at a time when absolute neutrophil count is < 0.5 × 109/liter.
PE, cisplatin etoposide; TP, topotecan-cisplatin; n.s., not significant.
Nonhematological toxicities were comparable in both treatment arms and did not 
show statistically significant differences.
TABLE 5.  Required Number of Transfusions/Growth Factors
Type of 
Transfusions/ 
Applications
Eto + Cis (PE) 
(n = 334) n (%) /  
No. of Transfusions
Topo + Cis (TP) 
(n = 346) 
n (%)/No. of Transfusions
Red blood cell 
transfusionsa
88 (26.4) 171 201 (58.1) 483
Platelet 
transfusions
14 (4.2) 24 34 (9.8) 50
G-CSF 12 (3.6) 34 34 (9.8) 78
Erythropoietin 45 (13.5) 61 63 (18.2) 116
aIntegrates a minimal number of whole blood transfusions not otherwise specified.
PE, cisplatin-etoposide; CSF, cerebrospinal fluid; TP, topotecan-cisplatin
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Topotecan, however, remains the first choice of treatment 
in the relapsed situation. A distinct monitoring of treat-
ment is warranted. For further significant improvements in 
ED-SCLC, more active targeted regimens with more favor-
able toxicity profiles are urgently needed.
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